175 related articles for article (PubMed ID: 8533580)
1. Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin.
Kimura M; Kuno-Sakai H; Kamiya H; Ueda K; Isomura S; Koike M; Kato T; Ozaki T; Hirose M; Egami T
Acta Paediatr Jpn; 1995 Oct; 37(5):562-74. PubMed ID: 8533580
[TBL] [Abstract][Full Text] [Related]
2. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
3. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
4. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
[TBL] [Abstract][Full Text] [Related]
5. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants.
Simondon F; Yam A; Gagnepain JY; Wassilak S; Danve B; Cadoz M
Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):927-32. PubMed ID: 9031875
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
[TBL] [Abstract][Full Text] [Related]
8. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children.
Pichichero ME; Badgett JT; Rodgers GC; McLinn S; Trevino-Scatterday B; Nelson JD
Pediatr Infect Dis J; 1987 Apr; 6(4):352-63. PubMed ID: 3495775
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children.
Halperin SA; Barreto L; Friesen B; Meekison W
Arch Pediatr Adolesc Med; 1994 May; 148(5):495-502. PubMed ID: 7910089
[TBL] [Abstract][Full Text] [Related]
10. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana.
Afari EA; Kamiya Y; Nkrumah FK; Dunyo SK; Akpedonu P; Kamiya H; Fukai F
Ann Trop Paediatr; 1996 Mar; 16(1):39-48. PubMed ID: 8787364
[TBL] [Abstract][Full Text] [Related]
12. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
[TBL] [Abstract][Full Text] [Related]
13. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
14. Acellular pertussis vaccines in infants: evaluation of single component and two-component products.
Anderson EL; Mink CM; Berlin BS; Shih CN; Tung FF; Belshe RB
Vaccine; 1994 Jan; 12(1):28-31. PubMed ID: 8303937
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
[TBL] [Abstract][Full Text] [Related]
16. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
[TBL] [Abstract][Full Text] [Related]
17. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
Cherry JD; Gornbein J; Heininger U; Stehr K
Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
[TBL] [Abstract][Full Text] [Related]
18. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
[TBL] [Abstract][Full Text] [Related]
19. Serum anti-PT and anti-FHA antibody levels, and agglutinin titers after administration of acellular pertussis vaccines.
Kuno-Sakai H; Kimura M; Sato Y; Tsunoda A; Urano T; Isomura S; Kamiya H
Acta Paediatr Jpn; 1989 Apr; 31(2):120-6. PubMed ID: 2516691
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
